Foundation Medicine Developing Targeted Sequencing Test for 'Clinically Actionable' Cancer Genes
April 13, 2011
Foundation Medicine Developing Targeted Sequencing Test for 'Clinically Actionable' Cancer Genes
The company is currently using the test, which analyzes several hundred cancer genes in tumors, in a pilot collaboration with Novartis and plans other partnerships with pharmaceutical firms and academic medical centers to demonstrate its analytical validity and clinical utility.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Entering NGS Space, Asuragen Launches Cancer Panels Optimized for FFPE on Ion Torrent and GA
January 4, 2012 / Clinical Sequencing News - Foundation Medicine Shows Sequencing-based Cancer Test Can ID Clinically Actionable Mutations
June 8, 2011 / Clinical Sequencing News - In Sequence Annual Survey: Illumina Leads Market but Most Users Believe PacBio Will Provide Next Big Leap
January 25, 2011 / In Sequence - At AACR, Labs Report NGS-based Cancer Genotyping on FFPE Samples Concordant with MassArray Panels
April 4, 2012 / Clinical Sequencing News - CHOP's Joint Genome Center Turns to Sequencing for MDx and Drug Repositioning
March 14, 2012 / Clinical Sequencing News